The Sepsis Diagnostics Market is segmented according to technology, product type, pathogen, application, end use, and region.

By technology, the market includes microbiology, molecular diagnostics, immunoassays, flow cytometry, and other technologies. Molecular diagnostics held approximately 36% of the market in 2025, supported by demand for rapid pathogen identification.

By product type, the market consists of instruments, blood culture media, assay kits and reagents, software, and related products. Assays and reagents represented approximately 52% of the market in 2025, benefiting from recurring laboratory consumable demand.

By pathogen, bacterial sepsis represents the largest segment, accounting for approximately 68% of the market. Fungal sepsis is expected to experience strong growth due to increasing diagnostic requirements among immunocompromised patient populations.

By diagnostic method, automated diagnostics account for the majority of market demand, supported by the need for improved workflow efficiency.

By end use, hospitals and clinics and diagnostic laboratories represent major market segments.

Regionally, North America leads the global market, Europe maintains a significant position, and Asia-Pacific is expected to register the fastest growth, with a projected CAGR of 8.9%.